Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy

The Journal of Thoracic and Cardiovascular Surgery

article

R. Taylor Ripley¹  Aaron S. Mansfield²  Boris Sepesi³  Raphael Bueno⁴  Bryan M. Burt¹ 

[1] Division of General Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine;Division of Medical Oncology, Mayo Clinic;Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center;Division of Thoracic Surgery, Brigham and Women"s Hospital

关键词: mesothelioma;    pleura;    checkpoint blockade;    immunotherapy;    checkpoint inhibitor;    nivolumab;    ipilimumab;   

DOI  :  10.1016/j.jtcvs.2022.01.020

学科分类：心脏病和心血管学

来源: Mosby, Inc.

【 摘 要 】

The landmark CheckMate 743 clinical trial of checkpoint blockade for malignant pleural mesothelioma (MPM) was published recently in the Lancet1 and, in short order, has changed clinical practice. This multinational, multi-institutional phase 3 trial randomized patients with untreated and unresectable MPM to dual-agent checkpoint blockade with anti-programmed cell death protein 1 (PD-1) (nivolumab) plus anti-cytotoxic T-lymphocyte antigen [CTLA]-4 therapy (ipilimumab) or systemic chemotherapy with cisplatin plus pemetrexed.

【 授权许可】

Unknown